Altimmune, Inc. (NASDAQ:ALT) Shares Sold by AXQ Capital LP

AXQ Capital LP reduced its position in shares of Altimmune, Inc. (NASDAQ:ALT) by 47.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,388 shares of the company’s stock after selling 11,107 shares during the period. AXQ Capital LP’s holdings in Altimmune were worth $89,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after buying an additional 74,194 shares in the last quarter. Bellevue Group AG raised its holdings in Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after acquiring an additional 263,660 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Altimmune by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in shares of Altimmune by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company’s stock valued at $1,482,000 after purchasing an additional 31,482 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Altimmune by 27.5% in the third quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock valued at $1,211,000 after purchasing an additional 42,553 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Analyst Ratings Changes

ALT has been the topic of a number of recent research reports. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. Stifel Nicolaus initiated coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Tuesday, March 18th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.83.

Insider Transactions at Altimmune

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction dated Thursday, March 13th. The shares were acquired at an average price of $5.20 per share, with a total value of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 4.10% of the company’s stock.

Altimmune Price Performance

NASDAQ ALT opened at $6.05 on Tuesday. The stock has a market capitalization of $465.93 million, a P/E ratio of -3.90 and a beta of 0.87. The firm’s 50-day moving average is $6.32 and its two-hundred day moving average is $7.09. Altimmune, Inc. has a 12 month low of $5.14 and a 12 month high of $11.16.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. As a group, analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.